Metabolic Predictors of Incident Coronary Heart Disease in Women

Background: Although metabolomic profiling offers promise for the prediction of coronary heart disease (CHD), and metabolic risk factors are more strongly associated with CHD in women than men, limited data are available for women. Methods: We applied a liquid chromatography–tandem mass spectrometry metabolomics platform to measure 371 metabolites in a discovery set of postmenopausal women (472 incident CHD cases, 472 controls) with validation in an independent set of postmenopausal women (312 incident CHD cases, 315 controls). Results: Eight metabolites, primarily oxidized lipids, were significantly dysregulated in cases after the adjustment for matching and CHD risk factors in both the discovery and validation data sets. One oxidized phospholipid, C34:2 hydroxy-phosphatidylcholine, remained associated with CHD after further adjustment for other validated metabolites. Subjects with C34:2 hydroxy-phosphatidylcholine levels in the highest quartile had a 4.7-fold increase in CHD odds in comparison with the lowest quartile; C34:2 hydroxy-phosphatidylcholine also significantly improved the area under the curve (P<0.01) for CHD. The C34:2 hydroxy-phosphatidylcholine findings were replicated in a third replication data set of 980 men and women (230 cardiovascular events) with a stronger association observed in women. Conclusions: These data replicate known metabolite predictors, identify novel markers, and support the relationship between lipid oxidation and subsequent CHD.

[1]  H. Yin,et al.  Comprehensive metabolomics identified lipid peroxidation as a prominent feature in human plasma of patients with coronary heart diseases , 2017, Redox biology.

[2]  Mark Woodward,et al.  Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus , 2016, Circulation.

[3]  L. Liang,et al.  Plasma Branched-Chain Amino Acids and Incident Cardiovascular Disease in the PREDIMED Trial. , 2016, Clinical chemistry.

[4]  Neil Pearce,et al.  Analysis of matched case-control studies , 2016, British Medical Journal.

[5]  Michael A. Wells,et al.  Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: a targeted metabolomics study[S] , 2016, Journal of Lipid Research.

[6]  K. Rexrode,et al.  Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus: A Scientific Statement From the American Heart Association. , 2015, Circulation.

[7]  Gender-specific pathway differences in the human serum metabolome , 2015, Metabolomics.

[8]  J. Murabito,et al.  Distinct Metabolomic Signatures Are Associated with Longevity in Humans , 2015, Nature Communications.

[9]  Tom R. Gaunt,et al.  Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. , 2015, Circulation.

[10]  Anders Larsson,et al.  Large-scale Metabolomic Profiling Identifies Novel Biomarkers for Incident Coronary Heart Disease , 2014, PLoS genetics.

[11]  T. Lehtimäki,et al.  A metabolic view on menopause and ageing , 2014, Nature Communications.

[12]  André M Deelder,et al.  A metabolomic profile is associated with the risk of incident coronary heart disease. , 2014, American heart journal.

[13]  M. Woodward,et al.  Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes , 2014, The Lancet.

[14]  Rebecca A Betensky,et al.  Variable selection and prediction using a nested, matched case‐control study: Application to hospital acquired pneumonia in stroke patients , 2014, Biometrics.

[15]  J. Marrugat,et al.  Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population. , 2014, Atherosclerosis.

[16]  E. Rimm,et al.  Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. , 2013, JAMA.

[17]  D. Mozaffarian,et al.  Mediterranean diet for primary prevention of cardiovascular disease. , 2013, The New England journal of medicine.

[18]  Thomas J. Wang,et al.  A diabetes-predictive amino acid score and future cardiovascular disease. , 2013, European heart journal.

[19]  T. Vasankari,et al.  Circulating oxidised LDL lipids, when proportioned to HDL-c, emerged as a risk factor of all-cause mortality in a population-based survival study. , 2013, Age and ageing.

[20]  E. Rimm,et al.  Association Between a Genetic Variant Related to Glutamic AcidMetabolism and Coronary Heart Disease in IndividualsWith Type 2 Diabetes , 2013 .

[21]  James R. Springstead,et al.  Role of Phospholipid Oxidation Products in Atherosclerosis , 2012, Circulation research.

[22]  Susan Cheng,et al.  Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans , 2012, Circulation.

[23]  W. Kraus,et al.  Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. , 2012, American heart journal.

[24]  Dolores Corella,et al.  Cohort profile: design and methods of the PREDIMED study. , 2012, International journal of epidemiology.

[25]  C. Serhan,et al.  Chiral lipidomics of E-series resolvins: aspirin and the biosynthesis of novel mediators. , 2011, Biochimica et biophysica acta.

[26]  C. Meisinger,et al.  Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. , 2011, Clinical chemistry.

[27]  Fabian J Theis,et al.  Discovery of Sexual Dimorphisms in Metabolic and Genetic Biomarkers , 2011, PLoS genetics.

[28]  Christophe Ladroue,et al.  Comparative Lipidomics Profiling of Human Atherosclerotic Plaques , 2011, Circulation. Cardiovascular genetics.

[29]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[30]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[31]  Geoffrey S Ginsburg,et al.  Association of a Peripheral Blood Metabolic Profile With Coronary Artery Disease and Risk of Subsequent Cardiovascular Events , 2010, Circulation. Cardiovascular genetics.

[32]  Bryan Langholz,et al.  Computational methods for case-cohort studies , 2007, Comput. Stat. Data Anal..

[33]  Y. Benjamini,et al.  Adaptive linear step-up procedures that control the false discovery rate , 2006 .

[34]  Carl J Pepine,et al.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. , 2006, Journal of the American College of Cardiology.

[35]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[36]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[37]  W E Barlow,et al.  Analysis of case-cohort designs. , 1999, Journal of clinical epidemiology.

[38]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[39]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .